Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers -DCC-3116 Selectively Targets ULK Kinase, an Initiating Protein that Activates Autophagy – -Company to Host a Webcast on Tuesday, June...
Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain NYX-2925 demonstrated statistically significant effects on a range of neuroimaging...
TigerConnect Named a Top Technology Company in Santa Monica 04.25.19 In the News Home / Newsroom /TigerConnect Named a Top Technology Company in Santa Monica Originally posted in The Tech Tribune Best Technology Company in Santa MonicaThe Tech Tribune staff has...
ARVINAS RECEIVES FAST TRACK DESIGNATION FOR ITS TARGETED PROTEIN DEGRADER ARV-110 AS A TREATMENT FOR MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER ARV-110 is Arvinas’ first clinical-stage drug in the innovative field of targeted protein degradation,...
Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers Favorable overall safety, tolerability, and pharmacokinetic profile—no serious adverse events reported across wide dose range Achieved ample CNS exposure...
Recent Comments